FDA Approves Unknown Drug — NORWICH
NORWICH announced FDA approval for ANDA217449 on June 17, a strategic regulatory milestone that positions the company for potential generic market entry and revenue diversification following patent exclusivity.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day